Cannabis use in youth is associated with chronic inflammation Authors: Emmet Power, David Mongan, Colm Healy, Subash Raj Susai, Melanie Föcking, Stanley Zammit, Mary Cannon, David Cotter Published: 2024 ABSTRACT AbstractBackgroundMarkers of inflammation and cannabis exposure are associated with an increased risk of mental disorders. In the current study, we investigated associations between cannabis use and biomarkers of inflammation.MethodsUtilizing a sample of 914 participants from the Avon Longitudinal Study of Parents and Children, we investigated whether interleukin-6 (IL-6), tumor necrosis factor α (TNFα), C-reactive protein (CRP), and soluble urokinase plasminogen activator receptor (suPAR) measured at age 24 were associated with past year daily cannabis use, less frequent cannabis use, and no past year cannabis use. We adjusted for a number of covariates including sociodemographic measures, body mass index, childhood trauma, and tobacco smoking. We found evidence of a strong association between daily or near daily cannabis use and suPAR.ResultsWe did not find any associations between less frequent cannabis use and suPAR. We did not find evidence of an association between IL-6, TNFα or CRP, and cannabis use.ConclusionsOur finding that frequent cannabis use is strongly associated with suPAR, a biomarker of systemic chronic inflammation implicated in neurodevelopmental and neurodegenerative processes is novel. These findings may provide valuable insights into biological mechanisms by which cannabis affects the brain and impacts the risk of serious mental disorders.Keywords: ALSPAC, cannabis, endocannabinoid, inflammation, suPAR, youth Introduction The impact of cannabis use on the development of serious and enduring mental illness has been a focus of research for over 120 years (Power, Healy, Murray, & Cannon, 2023). Cannabis use in youth has been linked to a range of deleterious neurodevelopmental outcomes including accelerated cortical thinning, declines in verbal intelligence and the development of psychotic disorders (Albaugh et al., 2023; Power et al., 2021, 2023). A recent umbrella review concluded that childhood trauma and cannabis use are the only two potentially modifiable risk factors associated with later psychosis that have strong prospective evidence (Arango et al., 2021). The potential mechanisms linking early cannabis use to later psychosis remain poorly understood although epidemiological evidence increasingly points toward the association being causal (Gage et al., 2017; Power et al., 2023). There are some conflicting lines of evidence within the available literature concerning long-term cannabis use and psychosis. Chronic cannabis use has been associated with decreased synthesis of dopamine in the striatum while increased dopamine synthesis in the striatum is generally accepted to be a neurobiological substrate of acute psychotic episodes (Bloomfield, Ashok, Volkow, & Howes, 2016; Murray et al., 2017). More recently, hypotheses have emerged implicating inflammation as a mechanism in the development of serious mental illness such as psychosis (Mongan, Ramesar, Föcking, Cannon, & Cotter, 2020). Mongan et al. (2020) in their review highlight that disruptions to the blood–brain barrier, activation of microglia, and abnormalities in the complement system may be implicated in excessive dendritic pruning characterized in psychotic disorders. In the case of cannabis use, the implication of neuroimmune function is of specific interest. Several lines of preclinical evidence from animal models show a persistent neuroinflammatory state resulting from adolescent Δ9-tetrahydrocannabinol (THC) exposure (De Meij et al., 2021; Moretti et al., 2014, 2015; Zamberletti, Gabaglio, Prini, Rubino, & Parolaro, 2015). These studies have suggested an effect from THC exposure in adolescence to later persistent neuroinflammation in adulthood and that THC may cause aberrations in neuroimmune development which later impact neurological integrity. One further recent study found that even low dose chronic THC treatment in adolescence resulted in increases in microglia expressing activated states associated with inflammatory processes in the brain and that these microglial changes persisted to adulthood (Lee et al., 2022). In this study, Lee and colleagues also found an enhanced neuroimmune response to subsequent social defeat stress including enhanced recruitment of peripheral monocytes to the brain leading to further microglia activation (Lee et al., 2022). The model described by Lee et al. (2022) is of specific interest as previous epidemiological evidence has suggested that severe stressors may moderate the risk of psychosis substantially in early onset cannabis users (Harley et al., 2010; Houston, Murphy, Adamson, Stringer, & Shevlin, 2008). A summary of both these studies showed that early onset cannabis use and severe stressors interact to increase the relative risk of subsequent psychosis more than 14-fold (Kiburi, Molebatsi, Ntlantsana, & Lynskey, 2021). These findings converge with evidence that cumulative stressful life events are related to peripheral soluble urokinase plasminogen activator receptor (suPAR), a marker of systemic chronic inflammation, in a dose–response manner (Bourassa et al., 2021). Daily cannabis use is known to be associated with downregulation of cannabinoid receptor 1 (CB1R) in a regionally specific manner, affecting the neocortex and limbic cortex but not subcortical structures or the cerebellum (Hirvonen et al., 2012). The relationship between CB1R and inflammation in the periphery has been described in animal models (Han & Kim, 2021). Previous studies have showed mixed results, however, with some suggesting that the endocannabinoid system exerts anti-inflammatory effects (Giacobbe, Marrocu, Di Benedetto, Pariante, & Borsini, 2021; Pacher, Steffens, Haskó, Schindler, & Kunos, 2018). A recent transcriptomic study has highlighted that the effect of THC on inflammation-related gene expression is nuanced and is not solely immunosuppressive (Hu et al., 2020). Pro-inflammatory effects may be related to dose, developmental sensitivity in timing of exposure, tissue type, and duration of exposure (Li, Watkins, & Wang, 2024; Moretti et al., 2014, 2015; Pacher et al., 2018; Zamberletti et al., 2015). A number of studies in humans investigating cannabis and biomarkers of inflammation have been carried out. Da Silva et al. (2019) used positron emission tomography (PET) imaging to measure in vivo brain levels of translocator protein (TSPO), an indicator of neuroinflammation, hypothesizing to find reduced TSPO in cannabis users. They found long-term cannabis users exhibited significantly higher TSPO levels in several brain regions compared to non-users. In contrast to their initial hypothesis they found increased brain TSPO with effect sizes of medium to large (Cohen's d = 0.6) and large (Cohen's d = 0.8) magnitudes in contrast to controls. A further PET study by the same group in a different set of samples replicated these findings showing similar effect-size associations between genetically predicted Complement component 4a protein (C4a) and TSPO, and cannabis use and TSPO (Da Silva et al., 2021). Notably both C4a and cannabis use are suggested to be implicated in the development of psychosis. Fernandez-Egea et al. (2013) found increased peripheral serum levels of C-C motif chemokine 11 (CCL11) in current cannabis users independent of tobacco use. CCL11 has previously been associated with neuroinflammatory processes, aging, and schizophrenia. A limited number of studies have investigated relationships between cannabis use and other peripheral inflammatory markers (interleukin-6 [IL-6], fibrinogen, C-reactive protein [CRP], IL-1β, and tumor necrosis factor α [TNFα]) in population samples (Corsi-Zuelli et al., 2022; Ferguson, Mannes, & Ennis, 2019; Okafor, Li, & Paltzer, 2020). These studies found no evidence of a direct association. Okafor et al. (2020) and Ferguson et al. (2019) measured past 30 day use as an exposure which may include many infrequent users. Corsi-Zuelli et al. (2022) found that inflammation may moderate the association between cannabis use and psychosis in early onset daily users, but found no linear association between cannabis use and inflammatory markers overall. No studies to date have investigated associations between cannabis use and suPAR. suPAR is known to be extensively implicated in neurodevelopmental and neurodegenerative processes, and innate immune responses in the brain (Cunningham et al., 2009). suPAR in serum is correlated with both cerebrospinal fluid (CSF) and albumin (Garcia-Monco, Coleman, & Benach, 2002). Elevated suPAR is found in an array of neurological and neuropsychiatric diseases (Garcia-Monco et al., 2002; Murphy et al., 2024). suPAR may also represent a more reliable measure of systemic chronic inflammation as it is less influenced by potential confounding factors such as intercurrent infection, medication use, and diurnal variation compared to IL-6 and CRP which are acute phase reactants (Rasmussen, Petersen, & Eugen-Olsen, 2021). suPAR is known to have high temporal stability (Rasmussen et al., 2021). suPAR is also hypothesized to predict subclinical end-organ damage and cellular inflammation whereas CRP is differentially hypothesized to predict metabolic inflammation (Lyngbæk et al., 2013). In the present study we aimed to investigate in a population sample whether cannabis use, characterized as daily/near daily use or other frequencies of past year use, was associated with measures of IL-6, TNFα, CRP, and suPAR. CB1R agonism is not associated with adverse metabolic or anthropometric changes in humans but is associated with altered mitochondrial respiration (Athanasiou et al., 2007; Meier et al., 2016; Meier, Pardini, Beardslee, & Matthews, 2019). In line with Lyngbæk et al. (2013) on the cellular v. metabolic inflammation differentiation hypothesis between suPAR and CRP: we hypothesized that elevated suPAR would be associated with cannabis use, whereas elevated CRP and related acute phase reactants, IL-6 and TNFα would not be associated with cannabis use. Methods Cohort profile The Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort is a longitudinal cohort study that enrolled 14 541 pregnant women resident in a defined geographical region in southwest England with expected dates of delivery between April 1st, 1991 and December 31st, 1992. From birth of the study subject, parents participated in regular surveys of the study subject's health and environment. From age 7 the children attended periodic assessment clinics in which they participated in clinical interviews and underwent physical tests. In total, 9958 participants were invited to attend clinic at the age 24, of whom 4019 attended the clinic and 3257 of whom provided a blood sample (Boyd et al., 2013; Fraser et al., 2013; Northstone et al., 2019). Ethical approval was received from the ALSPAC Law and Ethics Committee. Participants provided written informed consent and there was no financial compensation. For this analysis, we obtained local ethical approval from the Royal College of Surgeons in Ireland (REC1240cc). Consent for biological samples was collected in accordance with the Human Tissue Act 2004. Data were collected and managed using REDCap data capture tools (Harris et al., 2009, 2019). Note that the study website contains details of all the data that are available through a fully searchable data dictionary and variable search tool (http://www.bristol.ac.uk/alspac/researchers/our-data/). We report on a subgroup of 914 from the 3257 individuals who attended the age 24 clinic and provided a blood sample. Of the 914 individuals selected for analysis, 22.1% reported major depressive disorder, 29.32% reported generalized anxiety disorder, and 9.74% reported any past 6 month history of any psychotic symptoms. Inflammatory markers ALSPAC collected venous blood samples using a standardized protocol during a clinic visit when participants were age 24. Prior to phlebotomy, participants were requested to fast for 6 h. Samples were immediately spun and the plasma was separated and frozen at −80°C. Samples were subjected to one freeze–thaw cycle for aliquoting immediately prior to performing TNFα, CRP, and IL-6 assays. We analyzed the age 24 subsample with multiplex immunoassay kits. Plasma concentrations of TNFα and IL-6 were measured using the Proinflammatory Panel 1 (human) and CRP using Vascular Injury Panel 2 (human) kits (Meso Scale Discovery). For these markers, samples were measured in duplicate and we excluded cases from analysis where the coefficient of variation was >20% for quality control purposes. Plasma concentrations of suPAR were measured using a suPARnostic ELISA kit (Virogates) according to the manufacturer's instructions. A SpectraMax M3 microplate reader was used to measure optical densities. A standard curve was generated for each plate and plasma concentrations were interpolated using Virogates' custom results calculation tool (https://www.virogates.com/support). Standards were measured in duplicate and participant samples in singlet. All biomarker numerical outcome data are standardized to a mean of 0 and where 1 unit is equal to a 1 standard deviation (s.d.). Cannabis use Cannabis use frequency was measured by a single question with a number of response options for past year use. We grouped these responses into three coded options: (1) daily/almost daily use, (2) weekly or monthly use, (3) less frequent past year use, or (4) no use (representing the dummy variable). We chose to categorize cannabis as such to reflect likely types of use (non-use, experimental, recreational, and dependent). Covariates We adjusted for a range of covariates in a sequential manner aligned with previous described methods (O'Connor et al., 2009). We present unadjusted results, followed by a model adjusted for smoking status, body mass index (BMI), sex, and age in months. The third model is adjusted for early life sociodemographic measures (maternal education and family income), current alcohol dependency symptoms, and childhood trauma. The final model is adjusted for concurrent psychiatric comorbidity (generalized anxiety, moderate-to-severe depression, and experiencing psychotic symptoms in the past 6 months). BMI was measured at clinic visits using a wall-mounted stadiometer and electronic scales. Smoking status was coded as no past 30 day smoking, non-daily smoking in the past 30 days, and daily smoking. Depressive and anxiety disorders were measured by the Clinical Interview Schedule-Revised (CIS-R) at the age 24 ALSPAC clinic visit. The CIS-R classifies generalized anxiety disorder diagnosis as well as depression as mild, moderate, or severe based on symptom counts. The CIS-R instrument is a high specificity screening tool administered by trained lay interviewers in a computerized format (Brugha et al., 1999). We coded depression as a binomial variable with moderate-to-severe depression coded as 1 and mild and no depression coded as zero. Psychotic symptoms were measured using the PLIKSi which is a 12-item scale of measure of positive and thought interference symptoms of psychosis. This measure was rated by trained psychologists, where symptoms are rated as suspect, definite, or none. We coded symptoms as positive if their occurrence was definite, in the past 6 months and not attributable to sleep or fever (Horwood et al., 2008). Alcohol use was measured with the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score. The AUDIT-C score performs similarly to the full AUDIT screening tool in detecting hazardous drinking and/or alcohol abuse or dependence (Bush, Kivlahan, McDonell, Fihn, & Bradley, 1998). We utilized a previously described trauma classification within ALSPAC compiled from a mixture of contemporaneous subject and parent reports and age 22 subject retrospective reports (Croft et al., 2019). We selected five trauma variables including emotional neglect, emotional abuse, physical abuse, sexual abuse, and exposure to domestic violence. These variables were measured by time of exposure, from 0 to 4.9 years, 5 to 11.9 years, and 12 to 17.9 years. We coded each trauma exposure by summing the number of time point exposures. The range was 0–3 except for emotional neglect coded as 0–2 as it was not measured between 0 and 4.9 years. Statistical analysis We used Stata version 18 for statistical analysis. We loge-transformed values for suPAR, TNFα, IL-6, and CRP prior to analysis to account for skewness. We winsorized any outlying values to +/- 4 standard deviations. We used multivariate linear regression analyses to examine associations between endorsing cannabis use frequency and CRP, IL-6, and TNFα. We used multiple linear regression to investigate associations between past year cannabis use frequency and suPAR. We analyzed suPAR separately to other biomarkers as it is reportedly not an acute phase reactant and is proposed to reflect different aspects of inflammation (Lyngbæk et al., 2013). We used multiple imputation with chained equations to impute missing independent variable and covariate data with the ice package in Stata. We imputed 100 datasets for analyses for markers of missing exposure and covariate data separately (Graham, Olchowski, & Gilreath, 2007; Royston, 2014). We imputed for missing data using 35 variables to make the missing at random assumption more plausible. These included data points of parental income during the subject's gestation and childhood, the subject's substance and alcohol use history, mental health outcome data, parental home ownership, maternal post-natal depression, residency status (i.e. living with parents, in rented or owned accommodation), and current participation in employment and/or training. We used the mim package to apply Rubin's rules (Rubin, 1976, 2004). We report complete case analysis within our online Supplementary materials. Results Of the 914 subjects whose samples underwent suPAR measurements, 913 samples passed quality control. For the multiplex assay results, a lower number of samples passed quality control for all three biomarkers, totaling 767 samples. In Table 1 we provide the sample characteristics of the complete sample. Table 1.Sample characteristics%% missingExposures% Less than monthly use20.970.33% Weekly/monthly cannabis use6.890.33% Daily cannabis use4.70.33CovariatesEmotional abuse (%)20.8912.04Emotional neglect (%)7.3315.54Physical abuse (%)22.778.86Childhood sexual abuse (%)12.5827.38Domestic violence (%)13.8917.2Mean BMI (s.d.)24.83 (5.3)0Past-month non-daily smoking17.510.77Daily smoking14.220.77Median AUDIT-C score (IQR)5 (4–7)1.64Female62.250Mean age in months (s.d.)294.1 (9.4)0% Low-income household in pregnancy1.224.64Maternal education – degree level22.568.65Moderate/severe depression22.10.66Generalized anxiety29.320.44Psychotic symptoms in last 6 months9.740.88 Sample characteristics The prevalence of tobacco smoking was relatively high; 17.51% were non-daily past month smokers, and 14.22% were current daily smokers. Mean BMI was 24.83. Median and interquartile values of AUDIT-C scores were 5 and 4–7. There was little evidence of severe early life financial disadvantage. In total, 1.2% had a weekly household income of <100 pounds sterling during their gestation. Approximately 22.56% of subjects in both subgroups had mothers who were holders of university degrees during their gestation. Physical abuse (22.77%) and emotional abuse (20.89%) were the most common forms of childhood trauma reported. Other abuse types were less prevalent; 13.89% reported exposure to domestic violence, 7.33% reported emotional neglect, and 12.58% reported childhood sexual abuse. Daily use of cannabis was reported in 4.7%, weekly to monthly cannabis use was reported by a further 6.89%, and past year use which was less than monthly was reported by 20.97%. Sample characteristics did not substantially within complete case analysis (see online Supplementary eTable 1). IL-6, CRP, and TNFα findings In Tables 2–4,, we show the results of our findings investigating cannabis use and IL-6, CRP, and TNFα. Table 3.Multivariate regression analyses of associations between CRP, IL-6, TNFα, and cannabis use frequencies in 100 imputed samples (results for IL-6)aFrequency of cannabis useInflammatory markerLog IL-6Model 1βCIp valueFMI